🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Liu Huang clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Liu Huang as lead sponsor. Synced 26 Sep 2026
4Current trials
4Recruiting now
4Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Liu Huang is the lead sponsor of 4 current clinical trials in our China register. 4 are recruiting patients now. The most common phase is Phase 2. The drugs named most often in its trials are Fruquintinib, Cadonilimab and Glumetinib. The most-studied condition is Lung Cancer.

ClinicalTrials.gov trials by status

  • Recruiting4100%

Trials by phase

  • Phase 2125%
  • Not applicable125%
  • Phase 1/2125%
  • Observational125%
01

Clinical trials sponsored by Liu Huang

4 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer
NCT06199895 · ClinicalTrials.gov ↗ · Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer
Phase 2 Recruiting 2023-11 China
Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC
NCT06551207 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer
Not applicable Recruiting 2024-08 China
Glumetinib Combined With Fruquintinib in the Treatment of MET Amplification or Protein Overexpression in Third-Line Unresectable Metastatic Colorectal Cancer
NCT06980532 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer
Phase 1/2 Recruiting 2025-04 China
Exploratory Study of Precise Therapy for Advanced Tumor Patients With Malignant Hydrothorax or Ascites by Using PTC Drug Sensitivity Testing
NCT06413212 · ClinicalTrials.gov ↗ · Lung Cancer, Breast Cancer, Gastric Cancer
Observational Recruiting 2023-08 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Liu Huang trials

4 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Liu Huang trials

8 conditions
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China44

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Lung Cancer

SponsorTrials
Second Affiliated Hospital of Guangzhou Medical University10
Shanghai Chest Hospital9
Shanghai Pulmonary Hospital, Shanghai, China8
The First Affiliated Hospital of Guangzhou Medical University6
Intuitive Surgical4
Guangdong Provincial People's Hospital3
The Fourth Affiliated Hospital of Zhejiang University School of Medicine3
All India Institute of Medical Sciences2
Zhou Chengzhi2
Queen's University, Belfast1

Sponsors with the most current trials registered for this condition.

06

Questions about Liu Huang trials

How many clinical trials does Liu Huang sponsor?

Liu Huang is the lead sponsor of 4 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Liu Huang trials recruiting?

Yes. 4 of its 4 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Liu Huang testing?

Its current trials name 4 drugs and biologicals as interventions. The most frequent are Fruquintinib (2), Cadonilimab (1), Glumetinib (1) and Paclitaxel Polymeric Micelles (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.